Neuraptive Therapeutics has announced that its investigational drug, NTX-001, has been granted Breakthrough Therapy Designation by the FDA.

This designation could significantly speed up the development process for this therapy, which is intended for patients with peripheral nerve injuries needing repair. The designation follows promising results from the Phase 2 NEUROFUSE study and ongoing discussions with the FDA.

A pivotal Phase 3 trial of NTX-001 is planned to begin in early 2025. This trial will be a single, randomized, double-blind, placebo-controlled study to evaluate the treatment's efficacy and safety in patients with peripheral nerve injuries. The final details of the trial protocol are still being finalized with the FDA. Neuraptive expects to release the complete results, including 48-week data from the Phase 2 study, at an upcoming scientific conference.

Evan L. Zannis, Chief Operating Officer and Executive Vice President of Research and Development at Neuraptive Therapeutics, stated, "The Breakthrough Therapy Designation for NTX-001 represents a crucial step in our efforts to deliver cutting-edge treatments to individuals with peripheral nerve injuries. We look forward to advancing our collaboration with the FDA to bring NTX-001 to market as soon as possible and to contribute new advancements in nerve repair. We also appreciate the support of patients, researchers, and partners who have contributed to the development of NTX-001."

With this development, Neuraptive Therapeutics continues to lead the way in creating new solutions for those affected by peripheral nerve injuries worldwide.




Source: businesswire.com

Report Abuse